Skip to main content
. 2017 Jun 21;18(6):331–335. doi: 10.1002/jgf2.102

Figure 3.

Figure 3

Benefits and risks of low‐dose aspirin in primary prevention trials. The numbers of vascular events avoided and episodes of major bleeding caused by per 1000 patients treated with aspirin per year re plotted from the results of individual placebo‐controlled trials of aspirin in different patient populations characterized by various degrees of cardiovascular risk. WHS denotes Women's Health Study, PHS Physicians’ Health Study, PPP Primary Prevention Project, HOT Hypertension Optimal Treatment Study, BDT British Doctors Trial, TPT Thrombosis Prevention Trial, and SAPAT Swedish Angina Pectoris Aspirin Trial (quoted from reference 18)